ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

N/AApproved For MarketingNCT00040625

Eli Lilly and Company

Overview

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Study Type

EXPANDED_ACCESS

Conditions

Mesothelioma

Interventions

PemetrexedDRUG

CisplatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery * Prior chemotherapy for your disease is allowed * Measurable lesion is not required * Have a adequate performance status * Sign an informed consent form Exclusion Criteria: * You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study * You are excluded from this trial if you have received radiation within the previous 2 weeks * You are excluded from this trial if you are a candidates for curative surgery

Locations (6)

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.

Basking Ridge, New Jersey, United States

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician

Porto Alegre, Rio Grande do Sul, Brazil

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.